| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 64.86 | 223.7% |
| Total Income | 64.86 | 223.7% |
| Expenditure | 99.07 | 4.6% |
| PBT | — | |
| Net Profit | -42.67 | 49.7% |
| OPM | -52.73% | |
| NPM | -65.79% | |
| EPS | -0.48 | 51.0% |
Syndax Reports Q1 2026 Revenue of $64.9M, Up 224% Y-o-Y
03 May 2026 · 3 May, 6:06 pm
Summary
Syndax Pharmaceuticals reported its financial results for the first quarter ended March 31, 2026. Total revenue for the quarter was $64.9 million, a 224% increase year-over-year, driven by Revuforj net revenue of $48.9 million and Niktimvo collaboration revenue of $15.9 million. The company expects its operating expense base to remain stable and anticipates reaching profitability. Multiple clinical trials are ongoing, with new data expected throughout 2026.
Key Highlights
- 1
Syndax reported total revenue of $64.9 million in 1Q26, representing a 224% year-over-year increase.
- 2
Revuforj® net revenue reached $48.9 million in 1Q26, driven by increasing uptake in R/R NPM1m AML.
- 3
Niktimvo™ net revenue was $55.1 million in 1Q26, resulting in Syndax collaboration revenue of $15.9 million.
- 4
The company anticipates new revumenib real-world, frontline, and post-HSCT maintenance data in 2Q26.
- 5
Topline data from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD is expected in 4Q26.
- 6
Syndax expects total research and development plus selling, general and administrative expenses to be approximately $400 million for the full year of 2026.
Management Comments
Michael A. Metzger
"We delivered over $100 million in combined Revuforj and Niktimvo net sales in the first quarter, highlighting strong demand for our medicines and advancing the company towards profitability. Revuforj net revenue totaled $49 million, underscoring our leadership in menin inhibition and strong adoption in both R/R NPM1m AML and KMT2Ar acute leukemia. Notably, recent analysis indicates that Revuforj is enabling nearly half of KMT2A patients to receive a stem cell transplant, providing the best chance for durable remission and positioning the franchise for long-term growth as an increasing number of patients return to therapy post-transplant." "We are poised for continued commercial growth with robust prescriber bases, excellent payer coverage, and multiple evolving treatment patterns that should extend the average duration of treatment for both medicines." "We are nearing multiple important catalysts this year, including new Revuforj data which will further highlight its best-in-class profile and topline data from Phase 2 trials of Niktimvo in frontline chronic GVHD and IPF. As we look ahead, we are focused on unlocking the multi-billion-dollar opportunities for our medicines and are well-positioned to be first to frontline AML with a menin inhibitor, with strong global site initiation and patient enrollment underway in our pivotal trials."
Informational and educational content only. Not investment advice.